Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Ibrutinib significantly delays disease progression and extends survival in...

Dr John Byrd - The Ohio State University, Columbus, USA

Ibrutinib significantly delays disease progression and extends survival in resistant or relapsed CLL ( Dr John Byrd - The Ohio State University, Columbus, USA )

Emerging pathways in immunotherapy

Prof Christopher Höller - Medical University of Vienna, Vienna, Austria

Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )

Myeloma genomics and Immuno-oncology

Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio...

Myeloma genomics and Immuno-oncology ( Prof Keith Stewart; Prof Gareth Morgan; Dr Leif L. Bergsagel; Prof Antonio Palumbo )

Novel targets and immune based therapy in myeloma

Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San...

Novel targets and immune based therapy in myeloma ( Dr Kenneth Anderson; Prof Antonio Palumbo; Prof Gareth Morgan; Prof Jesús San Miguel )

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson

Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )

Recent advances in mantle cell lymphoma: Expert panel discussion

Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele...

Recent advances in mantle cell lymphoma: Expert panel discussion ( Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci )

Idelalisib shows promising results in patients with double refractory indolent...

Dr Andrew Davies - Southampton General Hospital, Southampton, UK;

$Idelalisib shows promising results in patients with double refractory indolent B-cell non-Hodgkin's lymphoma ( Dr Andrew Davies - Southampton General Hospital, Southampton, UK; )$

Rituximab versus idelalisib in refractory CLL

Prof John Gribben - Queen Mary University London, London, UK; Prof Peter...

$Rituximab versus idelalisib in refractory CLL ( Prof John Gribben - Queen Mary University London, London, UK; Prof Peter Hillmen - St James’ University Hospital, Leeds, UK )$

New agents extend progression-free survival in double refractory myeloma

Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta...

$New agents extend progression-free survival in double refractory myeloma ( Dr Jonathan Kaufman - Winship Cancer Institute of Emory University, Atlanta, USA )$

Aspirin analogues developed for anti-cancer effects on leukaemia

Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK

Aspirin analogues developed for anti-cancer effects on leukaemia ( Dr Chris Pepper - Cardiff University School of Medicine, Cardiff, UK )

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic...

Dr Valentin Goede - University of Cologne, Cologne, Germany

Use of GA101 and Clb preferable to rituximab in elderly or unfit chronic lymphocytic leukaemia patients ( Dr Valentin Goede - University of Cologne, Cologne, Germany )

New drug OTX15 shows early promise in fighting acute myeloid leukaemia

Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland

New drug OTX15 shows early promise in fighting acute myeloid leukaemia ( Dr Esteban Cvitkovic - Oncoethix, Lausanne, Switzerland )

More from ecancer